Author： Lee Ming-Han H. Graham Garry G. Williams Kenneth M. Day Richard O.
Publisher： Adis International
ISSN： 0114-5916
Source： Drug Safety, Vol.31, Iss.8, 2008-01, pp. : 643-665
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Access to resources
Recommend
ATP III update targets high-risk patients, statins market to benefit?
Inpharma, Vol. 1, Iss. 1447, 2004-01 ,pp. :
ATP III update targets high-risk patients, statins market to benefit?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 458, 2004-01 ,pp. :
Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. :
Benefit-Risk Assessment of Levetiracetam in the Treatment of Partial Seizures
Drug Safety, Vol. 28, Iss. 10, 2005-01 ,pp. :